LyondellBasell Industries N.V. R&D increased by 9.1% to $36.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.9%, from $34.00M to $36.00M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 2.3% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $32.00M | $30.00M | $33.00M | $32.00M | $32.00M | $31.00M | $29.00M | $33.00M | $32.00M | $31.00M | $34.00M | $32.00M | $33.00M | $31.00M | $39.00M | $34.00M | $35.00M | $34.00M | $33.00M | $36.00M |
| QoQ Change | — | -6.3% | +10.0% | -3.0% | +0.0% | -3.1% | -6.5% | +13.8% | -3.0% | -3.1% | +9.7% | -5.9% | +3.1% | -6.1% | +25.8% | -12.8% | +2.9% | -2.9% | -2.9% | +9.1% |
| YoY Change | — | — | — | — | +0.0% | +3.3% | -12.1% | +3.1% | +0.0% | +0.0% | +17.2% | -3.0% | +3.1% | +0.0% | +14.7% | +6.3% | +6.1% | +9.7% | -15.4% | +5.9% |